Evidence map›Paper›PMID 30669509›Full record

Trial reportInternational journal of molecular sciences2019

The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls.

Jonna Jalanka, Giles Major, Kathryn Murray, Gulzar Singh, Adam Nowak, Caroline Kurtz, Inmaculada Silos-Santiago, Jeffrey M Johnston, Willem M de Vos, Robin Spiller

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 204 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Jonna JalankaImmunobiology Research Program and Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, 00014 HY Helsinki, Finland. Jonna.Jalanka@helsinki.fi.ORCID 0000-0002-3847-8136
Giles MajorNottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust, the University of Nottingham, Notts NG7 2UH, UK. giles.major1@nottingham.ac.uk.ORCID 0000-0001-7944-3709
Kathryn MurrayNottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust, the University of Nottingham, Notts NG7 2UH, UK. Kathryn.Murray@nottingham.ac.uk.
Gulzar SinghNottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust, the University of Nottingham, Notts NG7 2UH, UK. Gulzar.Singh@nottingham.ac.uk.
Adam NowakNottingham University Hospitals NHS Trust, the University of Nottingham, Nottinghamshire NG5 1PB, UK. adam.nowak@nhs.net.
Caroline KurtzSynlogic therapeutics, Cambridge, MA 02142, USA. carolinebkurtz@gmail.com.
Inmaculada Silos-SantiagoDecibel Therapeutics Inc., Boston, MA 02215, USA. asilos@decibeltx.com.
Jeffrey M JohnstonNeurogastrx, Inc., Woburn, MA 01801, USA, formerly at Ironwood Pharmaceuticals, Cambridge, MA 02142, USA. jjohnston@neurogastrx.com.
Willem M de VosLaboratory of Microbiology, Wageningen University, 6708WE Wageningen, The Netherlands. willem.devos@wur.nl.ORCID 0000-0002-0273-3166
Robin SpillerNottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust, the University of Nottingham, Notts NG7 2UH, UK. Robin.Spiller@Nottingham.ac.uk.ORCID 0000-0001-6371-4500
Nottingham University Hospitals NHS Trust · GBDecImmune Therapeutics (United States) · USIronwood Pharmaceuticals (United States) · USSynlogic (United States) · USWageningen University & Research · NL

Funding

Academy of Finland 0313471-7Ironwood Pharmaceuticals Inc., Cambridge, MA, USA -
6 · The paper itself

Abstract

Psyllium is a widely used treatment for constipation. It traps water in the intestine increasing stool water, easing defaecation and altering the colonic environment. We aimed to assess the impact of psyllium on faecal microbiota, whose key role in gut physiology is being increasingly recognised. We performed two randomised, placebo-controlled, double-blinded trials comparing 7 days of psyllium with a placebo (maltodextrin) in 8 healthy volunteers and 16 constipated patients respectively. We measured the patients' gastrointestnal (GI) transit, faecal water content, short-chain fatty acid (SCFA) and the stool microbiota composition. While psyllium supplement had a small but significant effect on the microbial composition of healthy adults (increasing

Indexed as

AdultBacteriaCase-Control StudiesConstipationDouble-Blind MethodFatty Acids, VolatileFecesFemaleGastrointestinal MicrobiomeHumansMaleMiddle AgedPhylogenyPsylliumYoung AdultFatty Acids, VolatilePsylliumconstipationispaghulamicrobiomeprebioticstransit

Identifiers

PMID30669509
PMCPMC6358997
OpenAlexW2911132895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.